Comparison of two methods to assess variability of platelet response to anti-platelet therapies in patients with acute coronary syndrome undergoing angioplasty
The study investigated the clinical usefulness of a new method to evaluate platelet activation and the variability of platelet response to anti-platelet therapy in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Platelet activation was assessed in parallel by a new method...
Gespeichert in:
| Veröffentlicht in: | Thrombosis and haemostasis 2004-12, Vol.92 (6), p.1207-1213 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1213 |
|---|---|
| container_issue | 6 |
| container_start_page | 1207 |
| container_title | Thrombosis and haemostasis |
| container_volume | 92 |
| creator | Ahnadi, Charaf E. Boughrassa, Faiza F. Chapman-Montgomery, E. Sabrinah Poisson, Véronique Gervais, André Okrongly, David Grant, Andrew M. |
| description | The study investigated the clinical usefulness of a new method to evaluate platelet activation and the variability of platelet response to anti-platelet therapy in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Platelet activation was assessed in parallel by a new method for platelet density measurements (MPC, Mean Platelet Component Concentration), on the automated ADVIA 120 Hematology System and by the classic measurement of P-selectin (CD62P) expression, on a fluorescence flow cytometer. Patients received a loading dose of clopidogrel (300 mg; n = 29) or a bolus of abciximab (0.25 mg/kg; n = 15). Blood samples were collected before (baseline) and at different times after PTCA and antiplatelet drugs administration. Our data showed a close inverse correlation between the change in MPC and the CD62P fluo- rescence surface marker expression (r = - 0.776, P |
| doi_str_mv | 10.1160/TH04-02-0078 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1160_TH04_02_0078</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67156857</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-1008cacd27050c98ce4f548bba0a84ddd7c6a2c2014513529c548972aad40c293</originalsourceid><addsrcrecordid>eNqtkU2L1EAQhoMo7rh68yx98qLR7iSdj6MMqysseFnBW1Pp1Ex6SbpjV2WH-TX-VZOdYQXBm6eiqYenqvpNktdKflCqlB9vr2WRyiyVsqqfJJtMl1Va1s2Pp8lG5oVMy6zQF8kLojspVVk0-nlyobSu8yrTm-TXNowTREfBi7ATfAhiRO5DR4KDACIkEvcLAK0bHB9XaBqAcUAWEWkKnvAB9ezSxw73GGFySMJ5MQE79Ezi4LgXYGdGYUMMHuJR0NF3MYwoZt9h3Afn94tr78LiIj6-TJ7tYCB8da6XyffPV7fb6_Tm25ev2083qdVKc6qkrC3YLquklrapLRY7XdRtCxLqouu6ypaQ2UyqQqtcZ41duk2VAXSFtFmTXyZvT94php8zEpvRkcVhAI9hJlNWSpe1rhbw_Qm0MRBF3JkpunG5xChp1kDMGoiRmVkDWfA3Z-_cjtj9gc8JLMC7E8C9wxHNXZijXy79l86eaLI9MMOM8VHJ_fKPbSBHBnxnesAxEMP6tsHzmoCBaHt3j8YRzWhoQutgMCP4mWx0E5u8edjJ_ccpVa3_nmCoDwfT8zjkvwFyjenA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67156857</pqid></control><display><type>article</type><title>Comparison of two methods to assess variability of platelet response to anti-platelet therapies in patients with acute coronary syndrome undergoing angioplasty</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>Ahnadi, Charaf E. ; Boughrassa, Faiza F. ; Chapman-Montgomery, E. Sabrinah ; Poisson, Véronique ; Gervais, André ; Okrongly, David ; Grant, Andrew M.</creator><creatorcontrib>Ahnadi, Charaf E. ; Boughrassa, Faiza F. ; Chapman-Montgomery, E. Sabrinah ; Poisson, Véronique ; Gervais, André ; Okrongly, David ; Grant, Andrew M.</creatorcontrib><description>The study investigated the clinical usefulness of a new method to evaluate platelet activation and the variability of platelet response to anti-platelet therapy in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Platelet activation was assessed in parallel by a new method for platelet density measurements (MPC, Mean Platelet Component Concentration), on the automated ADVIA 120 Hematology System and by the classic measurement of P-selectin (CD62P) expression, on a fluorescence flow cytometer. Patients received a loading dose of clopidogrel (300 mg; n = 29) or a bolus of abciximab (0.25 mg/kg; n = 15). Blood samples were collected before (baseline) and at different times after PTCA and antiplatelet drugs administration. Our data showed a close inverse correlation between the change in MPC and the CD62P fluo- rescence surface marker expression (r = - 0.776, P<0.0001). Individual platelet activation determinations in patients receiving either clopidogrel or abciximab showed a variation in platelet activation as assayed by MPC and CD62P expression. Patients were characterized as having either high platelet activity upon admission and positive response to treatment or no detectable platelet activation before or after treatment. This study demonstrates the heterogeneity of platelet activation states in ACS patients undergoing coronary angioplasty. The present work also illustrates the potential use of the MPC parameter, generated on an automated hematology system, to define high risk patients and to monitor the variability of platelet response to anti-platelet therapies.</description><identifier>ISSN: 0340-6245</identifier><identifier>EISSN: 2567-689X</identifier><identifier>DOI: 10.1160/TH04-02-0078</identifier><identifier>PMID: 15583725</identifier><language>eng</language><publisher>Germany: Schattauer Verlag für Medizin und Naturwissenschaften</publisher><subject>Aged ; Angioplasty - methods ; Antibodies, Monoclonal - pharmacology ; Blood Platelets - drug effects ; Blood Platelets - metabolism ; Cell Count - methods ; Edetic Acid - chemistry ; Female ; Flow Cytometry - methods ; Fluorescent Dyes - pharmacology ; Heart Diseases - drug therapy ; Humans ; Immunoglobulin Fab Fragments - pharmacology ; Male ; Middle Aged ; P-Selectin - biosynthesis ; Platelet Activation - drug effects ; Platelet Aggregation Inhibitors - therapeutic use ; Risk ; Theme Issue Article ; Ticlopidine - analogs & derivatives ; Ticlopidine - pharmacology ; Time Factors</subject><ispartof>Thrombosis and haemostasis, 2004-12, Vol.92 (6), p.1207-1213</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-1008cacd27050c98ce4f548bba0a84ddd7c6a2c2014513529c548972aad40c293</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.thieme-connect.de/products/ejournals/pdf/10.1160/TH04-02-0078.pdf$$EPDF$$P50$$Gthieme$$H</linktopdf><linktohtml>$$Uhttps://www.thieme-connect.de/products/ejournals/html/10.1160/TH04-02-0078$$EHTML$$P50$$Gthieme$$H</linktohtml><link.rule.ids>314,777,781,3005,27905,27906,54540,54541</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15583725$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ahnadi, Charaf E.</creatorcontrib><creatorcontrib>Boughrassa, Faiza F.</creatorcontrib><creatorcontrib>Chapman-Montgomery, E. Sabrinah</creatorcontrib><creatorcontrib>Poisson, Véronique</creatorcontrib><creatorcontrib>Gervais, André</creatorcontrib><creatorcontrib>Okrongly, David</creatorcontrib><creatorcontrib>Grant, Andrew M.</creatorcontrib><title>Comparison of two methods to assess variability of platelet response to anti-platelet therapies in patients with acute coronary syndrome undergoing angioplasty</title><title>Thrombosis and haemostasis</title><addtitle>Thromb Haemost</addtitle><description>The study investigated the clinical usefulness of a new method to evaluate platelet activation and the variability of platelet response to anti-platelet therapy in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Platelet activation was assessed in parallel by a new method for platelet density measurements (MPC, Mean Platelet Component Concentration), on the automated ADVIA 120 Hematology System and by the classic measurement of P-selectin (CD62P) expression, on a fluorescence flow cytometer. Patients received a loading dose of clopidogrel (300 mg; n = 29) or a bolus of abciximab (0.25 mg/kg; n = 15). Blood samples were collected before (baseline) and at different times after PTCA and antiplatelet drugs administration. Our data showed a close inverse correlation between the change in MPC and the CD62P fluo- rescence surface marker expression (r = - 0.776, P<0.0001). Individual platelet activation determinations in patients receiving either clopidogrel or abciximab showed a variation in platelet activation as assayed by MPC and CD62P expression. Patients were characterized as having either high platelet activity upon admission and positive response to treatment or no detectable platelet activation before or after treatment. This study demonstrates the heterogeneity of platelet activation states in ACS patients undergoing coronary angioplasty. The present work also illustrates the potential use of the MPC parameter, generated on an automated hematology system, to define high risk patients and to monitor the variability of platelet response to anti-platelet therapies.</description><subject>Aged</subject><subject>Angioplasty - methods</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Blood Platelets - drug effects</subject><subject>Blood Platelets - metabolism</subject><subject>Cell Count - methods</subject><subject>Edetic Acid - chemistry</subject><subject>Female</subject><subject>Flow Cytometry - methods</subject><subject>Fluorescent Dyes - pharmacology</subject><subject>Heart Diseases - drug therapy</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - pharmacology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>P-Selectin - biosynthesis</subject><subject>Platelet Activation - drug effects</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Risk</subject><subject>Theme Issue Article</subject><subject>Ticlopidine - analogs & derivatives</subject><subject>Ticlopidine - pharmacology</subject><subject>Time Factors</subject><issn>0340-6245</issn><issn>2567-689X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqtkU2L1EAQhoMo7rh68yx98qLR7iSdj6MMqysseFnBW1Pp1Ex6SbpjV2WH-TX-VZOdYQXBm6eiqYenqvpNktdKflCqlB9vr2WRyiyVsqqfJJtMl1Va1s2Pp8lG5oVMy6zQF8kLojspVVk0-nlyobSu8yrTm-TXNowTREfBi7ATfAhiRO5DR4KDACIkEvcLAK0bHB9XaBqAcUAWEWkKnvAB9ezSxw73GGFySMJ5MQE79Ezi4LgXYGdGYUMMHuJR0NF3MYwoZt9h3Afn94tr78LiIj6-TJ7tYCB8da6XyffPV7fb6_Tm25ev2083qdVKc6qkrC3YLquklrapLRY7XdRtCxLqouu6ypaQ2UyqQqtcZ41duk2VAXSFtFmTXyZvT94php8zEpvRkcVhAI9hJlNWSpe1rhbw_Qm0MRBF3JkpunG5xChp1kDMGoiRmVkDWfA3Z-_cjtj9gc8JLMC7E8C9wxHNXZijXy79l86eaLI9MMOM8VHJ_fKPbSBHBnxnesAxEMP6tsHzmoCBaHt3j8YRzWhoQutgMCP4mWx0E5u8edjJ_ccpVa3_nmCoDwfT8zjkvwFyjenA</recordid><startdate>20041201</startdate><enddate>20041201</enddate><creator>Ahnadi, Charaf E.</creator><creator>Boughrassa, Faiza F.</creator><creator>Chapman-Montgomery, E. Sabrinah</creator><creator>Poisson, Véronique</creator><creator>Gervais, André</creator><creator>Okrongly, David</creator><creator>Grant, Andrew M.</creator><general>Schattauer Verlag für Medizin und Naturwissenschaften</general><general>Schattauer GmbH</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20041201</creationdate><title>Comparison of two methods to assess variability of platelet response to anti-platelet therapies in patients with acute coronary syndrome undergoing angioplasty</title><author>Ahnadi, Charaf E. ; Boughrassa, Faiza F. ; Chapman-Montgomery, E. Sabrinah ; Poisson, Véronique ; Gervais, André ; Okrongly, David ; Grant, Andrew M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-1008cacd27050c98ce4f548bba0a84ddd7c6a2c2014513529c548972aad40c293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Angioplasty - methods</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Blood Platelets - drug effects</topic><topic>Blood Platelets - metabolism</topic><topic>Cell Count - methods</topic><topic>Edetic Acid - chemistry</topic><topic>Female</topic><topic>Flow Cytometry - methods</topic><topic>Fluorescent Dyes - pharmacology</topic><topic>Heart Diseases - drug therapy</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - pharmacology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>P-Selectin - biosynthesis</topic><topic>Platelet Activation - drug effects</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Risk</topic><topic>Theme Issue Article</topic><topic>Ticlopidine - analogs & derivatives</topic><topic>Ticlopidine - pharmacology</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ahnadi, Charaf E.</creatorcontrib><creatorcontrib>Boughrassa, Faiza F.</creatorcontrib><creatorcontrib>Chapman-Montgomery, E. Sabrinah</creatorcontrib><creatorcontrib>Poisson, Véronique</creatorcontrib><creatorcontrib>Gervais, André</creatorcontrib><creatorcontrib>Okrongly, David</creatorcontrib><creatorcontrib>Grant, Andrew M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahnadi, Charaf E.</au><au>Boughrassa, Faiza F.</au><au>Chapman-Montgomery, E. Sabrinah</au><au>Poisson, Véronique</au><au>Gervais, André</au><au>Okrongly, David</au><au>Grant, Andrew M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of two methods to assess variability of platelet response to anti-platelet therapies in patients with acute coronary syndrome undergoing angioplasty</atitle><jtitle>Thrombosis and haemostasis</jtitle><addtitle>Thromb Haemost</addtitle><date>2004-12-01</date><risdate>2004</risdate><volume>92</volume><issue>6</issue><spage>1207</spage><epage>1213</epage><pages>1207-1213</pages><issn>0340-6245</issn><eissn>2567-689X</eissn><abstract>The study investigated the clinical usefulness of a new method to evaluate platelet activation and the variability of platelet response to anti-platelet therapy in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Platelet activation was assessed in parallel by a new method for platelet density measurements (MPC, Mean Platelet Component Concentration), on the automated ADVIA 120 Hematology System and by the classic measurement of P-selectin (CD62P) expression, on a fluorescence flow cytometer. Patients received a loading dose of clopidogrel (300 mg; n = 29) or a bolus of abciximab (0.25 mg/kg; n = 15). Blood samples were collected before (baseline) and at different times after PTCA and antiplatelet drugs administration. Our data showed a close inverse correlation between the change in MPC and the CD62P fluo- rescence surface marker expression (r = - 0.776, P<0.0001). Individual platelet activation determinations in patients receiving either clopidogrel or abciximab showed a variation in platelet activation as assayed by MPC and CD62P expression. Patients were characterized as having either high platelet activity upon admission and positive response to treatment or no detectable platelet activation before or after treatment. This study demonstrates the heterogeneity of platelet activation states in ACS patients undergoing coronary angioplasty. The present work also illustrates the potential use of the MPC parameter, generated on an automated hematology system, to define high risk patients and to monitor the variability of platelet response to anti-platelet therapies.</abstract><cop>Germany</cop><pub>Schattauer Verlag für Medizin und Naturwissenschaften</pub><pmid>15583725</pmid><doi>10.1160/TH04-02-0078</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-6245 |
| ispartof | Thrombosis and haemostasis, 2004-12, Vol.92 (6), p.1207-1213 |
| issn | 0340-6245 2567-689X |
| language | eng |
| recordid | cdi_crossref_primary_10_1160_TH04_02_0078 |
| source | MEDLINE; Thieme Connect Journals |
| subjects | Aged Angioplasty - methods Antibodies, Monoclonal - pharmacology Blood Platelets - drug effects Blood Platelets - metabolism Cell Count - methods Edetic Acid - chemistry Female Flow Cytometry - methods Fluorescent Dyes - pharmacology Heart Diseases - drug therapy Humans Immunoglobulin Fab Fragments - pharmacology Male Middle Aged P-Selectin - biosynthesis Platelet Activation - drug effects Platelet Aggregation Inhibitors - therapeutic use Risk Theme Issue Article Ticlopidine - analogs & derivatives Ticlopidine - pharmacology Time Factors |
| title | Comparison of two methods to assess variability of platelet response to anti-platelet therapies in patients with acute coronary syndrome undergoing angioplasty |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T18%3A30%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20two%20methods%20to%20assess%20variability%20of%20platelet%20response%20to%20anti-platelet%20therapies%20in%20patients%20with%20acute%20coronary%20syndrome%20undergoing%20angioplasty&rft.jtitle=Thrombosis%20and%20haemostasis&rft.au=Ahnadi,%20Charaf%20E.&rft.date=2004-12-01&rft.volume=92&rft.issue=6&rft.spage=1207&rft.epage=1213&rft.pages=1207-1213&rft.issn=0340-6245&rft.eissn=2567-689X&rft_id=info:doi/10.1160/TH04-02-0078&rft_dat=%3Cproquest_cross%3E67156857%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67156857&rft_id=info:pmid/15583725&rfr_iscdi=true |